News >

Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL

Danielle Bucco
Published: Wednesday, Oct 18, 2017

Narendranath Epperla, MD

Narendranath Epperla, MD
Clinical trials exploring novel combination regimens continue to advanced the treatment landscape for patients with follicular lymphoma and mantle cell lymphoma (MCL).

on Hematologic Malignancies, Epperla, assistant professor of internal medicine, Department of Medicine, Division of Hematology, The Ohio State University, discussed the evolving treatment landscape for patients with follicular lymphoma and MCL.

OncLive®: Can you please provide an overview of your lecture?

Epperla: The GALLIUM study looked at using obinutuzumab plus chemotherapy versus rituximab and chemotherapy. Obinutuzumab and chemotherapy had improved response rates and PFS. However, one needs to note that it was obinutuzumab plus chemotherapy followed by obinutuzumab maintenance, or rituximab plus chemotherapy followed by rituximab maintenance. One should be aware of the side effect profile when giving obinutuzumab and chemotherapy as an infusion, but it is an exciting time in the field.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication